Move expands inoculation program as vaccination rates slow
The Pfizer-BioNTech Covid-19 vaccine has been authorized in the US for children as young as 12.
US regulators on Monday authorized Pfizer and its partner BioNTech’s Covid-19 vaccine for use in children as young as 12, widening the country’s inoculation program even as vaccination rates have slowed significantly.
The vaccine has been available under an emergency use authorization (EUA) to people as young as 16 in the United States.
The vaccine makers said they had started the process for full approval for those ages last week.
The US Food and Drug Administration said it was amending the EUA to include the millions of children aged 12 to 15.